The transition from normal aging to mild cognitive impairment to Alzheimer disease (AD) is often indistinct. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Research
27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Typical normative models appear appropriate for remote self‐administered measures and are sensitive to cognitive impairment. 3 key findings →
Participants: 167 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Over 15 years of follow-up (UKB), moderate or high CVH versus low CVH was associated with a lower risk of MCI (hazard ratio 0.82 [95% CI 0.71, 0.95], P < 0.05) but not with risk of all-cause dementia (0.97 [0.84, 1.11], P = 0.63). 4 key findings →
Participants: 41,374 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Internal consistency of the ACE-III was strong (McDonald's ω = 0.889). 4 key findings →
Participants: 1,265 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Aβ + CN individuals performed worse than Aβ-CN participants in the SCBC while the SOC only distinguished Aβ − CN from MCI participants. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Accurate estimation of Alzheimer's disease (AD) severity from structural magnetic resonance imaging (MRI) remains difficult, as disease-associated anatomical alterations are often subtle and publicly available datasets are typically too small to support robust deep learning model training. 1 key finding →
Participants: 214 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of 44,899 MCI patients, 6391 progressed to AD. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
42/100
Gender has an impact on CR, but not through socio‐economic variables. 2 key findings →
Participants: 440 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Forty-four physicians, primarily neurologists (n = 31; 70.5 %), were interviewed. 5 key findings →
Participants: 31 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Making early and informative diagnoses of mild cognitive impairment (MCI) is highly important for planning timely and appropriate interventions aimed at dementia risk reduction. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Fifty-nine patients fulfilled the inclusion criteria. 5 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
All volumes showed the smallest in dementia, the intermediate in MCI, and the largest in healthy controls. 5 key findings →
Design: cross-sectional Participants: 1,536 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
42/100
A total of 90 (38.96%) participants were healthy and 141 (61.04%) had MCI. 5 key findings →
Design: cross-sectional Participants: 231 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The MoCA score and the SCWT duration of the real group improved significantly compared with that of the sham group. 5 key findings →
Participants: 18 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Sixteen of 30 cases with DLB pathology had no parkinsonism, which represented diverse nigral neurodegeneration. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Tri demonstrates significant multi-target neuroprotective effects in AD preclinical models. 2 key findings →
Design: systematic review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We conclude that an inverse correlation between levels of inflammation in cortical areas and plasma NfL levels indicates that microglial activation may initially be protective to axons in AD. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We tested association of nine late-onset Alzheimer's disease (LOAD) risk variants from genome-wide association studies (GWAS) with memory and progression to mild cognitive impairment (MCI) or LOAD (MCI/LOAD) in older Caucasians, cognitively normal at baseline and longitudinally evaluated at Mayo Clinic Rochester and Jacksonville (n>2000). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer disease (AD) is an age-related neurodegenerative disorder, characterized histopathologically by the presence of senile plaques (SP), neurofibrillary tangles and synapse loss in selected brain regions. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Natural Language Processing (NLP) is an ever-growing field of computational science that aims to model natural human language. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Numerous studies have shown a marked decrease of beta-amyloid(42) (Abeta(42)) in the cerebrospinal fluid (CSF) of patients with incipient Alzheimer's disease (AD). 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
A multitiered strategy was adopted to assess tau conformational changes within fibrillar lesions during the progression of Alzheimer's disease (AD). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Increasing evidence suggests that free radical-mediated oxidation of biological substrates is a key feature of Alzheimer's disease (AD) pathogenesis. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Decline in olfactory activity was correlated with the AD structural degeneration in the POC. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Data support the evidence that neuropsychological rehabilitation is effective in Alzheimer disease (AD), to strengthen the pharmacological treatment to delay the progression of dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
From across this tag
10 of the 2,141 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- DTI measures in crossing-fibre areas: increased diffusion anisotropy reveals early white matter alteration in MCI and mild Alzheimer's disease
- Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease
- The analysis of the gut microbiome during liver disease progression led to the identification of biomarkers for related mild cognitive impairment
- Identifying Exercise Interventions That May Slow the Progression of Cognitive Decline in Older Adults With Mild Cognitive Impairment: A Scoping Review
- Restriction in complex activities of daily living in MCI: impact on outcome
- Effects of physical exercise on cognitive function of older adults with mild cognitive impairment: A systematic review and meta-analysis
- Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment
- Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias
- Falls, Cognitive Impairment, and Gait Performance: Results From the GOOD Initiative
- Early versus late MCI: Improved MCI staging using a neuropsychological approach
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →